Pieris Pharmaceuticals, Inc. (PIRS): Price and Financial Metrics
Pieris Pharmaceuticals, Inc. (PIRS)
Today's Latest Price: $2.25 USD
Updated Oct 23 4:00pm
Add PIRS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
PIRS Stock Summary
- Of note is the ratio of Pieris Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 13.56% of US stocks have a lower such ratio.
- Revenue growth over the past 12 months for Pieris Pharmaceuticals Inc comes in at 109.72%, a number that bests 95.09% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PIRS comes in at -28.61% -- higher than that of only 13.83% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Pieris Pharmaceuticals Inc, a group of peers worth examining would be CDTX, NXTC, MGEN, SYBX, and KALV.
- PIRS's SEC filings can be seen here. And to visit Pieris Pharmaceuticals Inc's official web site, go to www.pieris.com.
PIRS Stock Price Chart Interactive Chart >
PIRS Price/Volume Stats
| Current price | $2.25 | 52-week high | $4.30 |
| Prev. close | $2.26 | 52-week low | $1.60 |
| Day low | $2.19 | Volume | 224,900 |
| Day high | $2.29 | Avg. volume | 463,033 |
| 50-day MA | $2.55 | Dividend yield | N/A |
| 200-day MA | $2.89 | Market Cap | 117.90M |
Pieris Pharmaceuticals, Inc. (PIRS) Company Bio
Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is based in Boston, Massachusetts.
Loading social stream, please wait...